Pomerantz LLP is investigating Dr. Reddy's Laboratories for possible securities fraud following the company's Q1 fiscal 2027 earnings report. The report revealed earnings per share of $0.06, negatively impacted by a ₹2.4 billion provision for out-of-specification semaglutide batches. This led to a 9.4% drop in the stock price. The investigation will determine if Dr. Reddy's and its executives engaged in unlawful business practices, affecting investor confidence and potentially leading to legal action.
Regarding Dr. Reddy's Laboratories Limited, here is Pluang's health sector market snapshot as of Sep 25, 2026 05:51 WIB: Out of 100 priced health-sector US stocks tradable on Pluang, 40 rose and 60 fell today. Notable movers include NUWE at USD 0.80 with a 1-day change of -5.77%, DGX at USD 232.90 down 5.51%, and OSCR at USD 28.89 down 5.37%.
TD SYNNEX posted a record-breaking quarter in Q3 2026 with earnings and revenue surpassing expectations, driven by strong growth in its Hyve Solutions segment and AI infrastructure demand. Despite this, the stock dropped nearly 9% due to a nearly $1 ...
A crypto whale transferred 6,000 Ether (ETH), worth approximately $16.1 million, to five major cryptocurrency exchanges: OKX, Kraken, Gate, Bybit, and Binance. This large transfer places a significant amount of ETH on trading platforms, suggesting th...
Warren Buffett increased his stake in homebuilder Lennar to over 10% immediately after the company missed earnings and lowered its full-year delivery forecast. Despite Lennar's recent weak quarter, Buffett's move signals confidence in the long-term h...
TRON has exceeded $30 trillion in total transaction volume, marking its evolution into a high-throughput settlement network. Daily transactions exceed $30 billion, supported by over 405 million users and 15.6 billion processed transactions, mainly dr...
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
